scholarly journals The brain-derived neurotrophic factor (BDNF) val66met polymorphism differentially affects performance on subscales of the Wechsler Memory Scale – Third Edition (WMS-III)

2015 ◽  
Vol 6 ◽  
Author(s):  
Yvette N. Lamb ◽  
Christopher S. Thompson ◽  
Nicole S. McKay ◽  
Karen E. Waldie ◽  
Ian J. Kirk
Keyword(s):  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Val66met Polymorphism ◽  
Wechsler Memory Scale ◽  
Bdnf Val66met Polymorphism ◽  
The Brain

scholarly journals Cerebral 5-HT2A Receptor and Serotonin Transporter Binding in Humans Are Not Affected by the val66met BDNF Polymorphism Status or Blood BDNF Levels

2010 ◽  
Vol 30 (11) ◽  
pp. e1-e7 ◽  
Author(s):  
Anders Bue Klein ◽  
Viktorija Trajkovska ◽  
David Erritzoe ◽  
Steven Haugbol ◽  
Jacob Madsen ◽  
...  
Keyword(s):  
Serotonin Transporter ◽  
Receptor Binding ◽  
Neurotrophic Factor ◽  
Healthy Subjects ◽  
Brain Derived Neurotrophic Factor ◽  
Serotonergic System ◽  
Val66met Polymorphism ◽  
Serotonin System ◽  
Bdnf Val66met Polymorphism ◽  
The Brain

Recent studies have proposed an interrelation between the brain-derived neurotrophic factor (BDNF) val66met polymorphism and the serotonin system. In this study, we investigated whether the BDNF val66met polymorphism or blood BDNF levels are associated with cerebral 5-hydroxytryptamine 2A (5-HT2A) receptor or serotonin transporter (SERT) binding in healthy subjects. No statistically significant differences in 5-HT2A receptor or SERT binding were found between the val/val and met carriers, nor were blood BDNF values associated with SERT binding or 5-HT2A receptor binding. In conclusion, val66met BDNF polymorphism status is not associated with changes in the serotonergic system. Moreover, BDNF levels in blood do not correlate with either 5-HT2A or SERT binding.

scholarly journals The genetic influence of the brain-derived neurotrophic factor Val66Met polymorphism in chronic low back pain

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Angela Shiratsu Yamada ◽  
Flavia Tasmim Techera Antunes ◽  
Camila Ferraz ◽  
Alessandra Hubner de Souza ◽  
Daniel Simon
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Neurotrophic Factor ◽  
Central Sensitization ◽  
Low Back ◽  
Bdnf Gene ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism ◽  
The Brain

Abstract Background The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP). Methods A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism. Results The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP. Conclusion The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

Sign in / Sign up

Export Citation Format

Share Document